AbbVie (ABBV) Total Current Liabilities (2012 - 2026)

AbbVie (ABBV) has reported Total Current Liabilities for 15 consecutive years, with $41.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 4.71% year-over-year to $41.6 billion in Q2 2026; TTM through Jun 2026 was $41.6 billion, a 4.71% increase from a year earlier, with the FY2025 full-year figure at $43.3 billion, up 11.72% from the prior year.
• Total Current Liabilities was $41.6 billion for Q2 2026 at AbbVie, down from $42.1 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $43.3 billion in Q4 2025 and troughed at $27.6 billion in Q1 2023.
• A 5-year average of $37.2 billion and a median of $38.3 billion in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities fell 16.07% in 2022 and soared 50.5% in 2024, its largest moves.
• Over 5 years, Total Current Liabilities stood at $29.5 billion in 2022, then grew by 28.11% to $37.8 billion in 2023, then climbed by 2.4% to $38.7 billion in 2024, then climbed by 11.72% to $43.3 billion in 2025, then retreated by 3.8% to $41.6 billion in 2026.
• The last three Total Current Liabilities figures came in at $41.6 billion (Q2 2026), $42.1 billion (Q1 2026), and $43.3 billion (Q4 2025), per Business Quant data.